(Q34157698)

31 July 2017

title

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study (English)

1 reference

31 July 2017

1 reference

Dannon PN

1

1 reference

31 July 2017

Iancu I

series ordinal

2

1 reference

31 July 2017

Grunhaus L

series ordinal

3

1 reference

31 July 2017

publication date

1 October 2002

1 reference

31 July 2017

published in

Human Psychopharmacology

1 reference

31 July 2017

volume

17

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

329-333

1 reference

Brain circuits in panic disorder

31 July 2017

cites work

1 reference

Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action

21 January 2018

1 reference

Panic disorder. Pathophysiology and drug treatment

21 January 2018

1 reference

Desipramine treatment in panic disorder

21 January 2018

1 reference

Psychiatric reaction patterns to imipramine

21 January 2018

1 reference

21 January 2018

1 reference

Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.

21 January 2018

1 reference

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder

21 January 2018

1 reference

The cross-national epidemiology of panic disorder

21 January 2018

1 reference

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

21 January 2018

1 reference

7 January 2021

Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?

1 reference

7 January 2021

The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial

1 reference

7 January 2021

Continuing dialogue on incentive bias.

1 reference

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

7 January 2021

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

7 January 2021

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder

1 reference

7 January 2021

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

1 reference

7 January 2021

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline

1 reference

7 January 2021

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

1 reference

7 January 2021

Brain noradrenaline and the mechanisms of action of antidepressant drugs.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.421

1 reference

31 July 2017

1 reference